tiprankstipranks
Trending News
More News >
Globus Medical (GMED)
NYSE:GMED
US Market

Globus Medical (GMED) Stock Forecast & Price Target

Compare
944 Followers
See the Price Targets and Ratings of:

GMED Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
9 Buy
4 Hold
0 Sell
Based on 13 analysts giving stock ratings to
Globus
Medical
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GMED Stock 12 Month Forecast

Average Price Target

$105.60
▲(12.98% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for Globus Medical in the last 3 months. The average price target is $105.60 with a high forecast of $118.00 and a low forecast of $87.00. The average price target represents a 12.98% change from the last price of $93.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"51":"$51","68":"$68","85":"$85","102":"$102","119":"$119"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":118,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$118.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$105.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":87,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$87.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[51,68,85,102,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.31,89.67076923076924,92.03153846153846,94.3923076923077,96.75307692307692,99.11384615384615,101.47461538461539,103.83538461538461,106.19615384615385,108.55692307692308,110.9176923076923,113.27846153846154,115.63923076923078,{"y":118,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.31,88.71692307692308,90.12384615384616,91.53076923076924,92.9376923076923,94.34461538461538,95.75153846153846,97.15846153846154,98.56538461538462,99.9723076923077,101.37923076923076,102.78615384615384,104.19307692307692,{"y":105.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,87.31,87.28615384615385,87.2623076923077,87.23846153846154,87.21461538461539,87.19076923076923,87.16692307692308,87.14307692307692,87.11923076923077,87.09538461538462,87.07153846153847,87.0476923076923,87.02384615384615,{"y":87,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":82.71,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.32,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":73.39,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.11,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.96,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.2,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.79,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$118.00Average Price Target$105.60Lowest Price Target$87.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GMED
Bank of America Securities
Bank of America Securities
$106
Buy
13.41%
Upside
Reiterated
01/16/26
Globus Medical (GMED) Gets a Buy from Bank of America Securities
Canaccord Genuity Analyst forecast on GMED
Canaccord Genuity
Canaccord Genuity
$105$112
Buy
19.82%
Upside
Reiterated
01/09/26
Canaccord Genuity Remains a Buy on Globus Medical (GMED)
Truist Financial Analyst forecast on GMED
Truist Financial
Truist Financial
Buy
Reiterated
01/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Neogen (NASDAQ: NEOG), Radnet (NASDAQ: RDNT) and Globus Medical (NYSE: GMED)
Jefferies
$105$115
Buy
23.03%
Upside
Reiterated
01/08/26
Jefferies Sticks to Its Buy Rating for Globus Medical (GMED)
Barclays Analyst forecast on GMED
Barclays
Barclays
$114$118
Buy
26.24%
Upside
Reiterated
01/08/26
Barclays Keeps Their Buy Rating on Globus Medical (GMED)
Stifel Nicolaus Analyst forecast on GMED
Stifel Nicolaus
Stifel Nicolaus
$76$90
Hold
-3.71%
Downside
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Globus Medical (NYSE: GMED) and Verrica Pharmaceuticals (NASDAQ: VRCA)
Wells Fargo Analyst forecast on GMED
Wells Fargo
Wells Fargo
$98
Buy
4.85%
Upside
Reiterated
01/08/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Globus Medical (GMED)
Needham
Hold
Reiterated
01/08/26
Globus Medical: Strong Fundamentals and Outperformance Largely Priced In, Justifying a Hold Rating
Piper Sandler Analyst forecast on GMED
Piper Sandler
Piper Sandler
$90$115
Buy
23.03%
Upside
Reiterated
01/08/26
Piper Sandler Reaffirms Their Buy Rating on Globus Medical (GMED)
RBC Capital
$100$115
Buy
23.03%
Upside
Reiterated
01/07/26
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)
BTIG
Hold
Reiterated
01/07/26
Globus Medical: Strong Execution and Upside Revisions Balanced by Full Valuation Support Hold Rating
Freedom Capital Markets Analyst forecast on GMED
Freedom Capital Markets
Freedom Capital Markets
$87
Hold
-6.92%
Downside
Initiated
12/16/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Globus Medical (NYSE: GMED)
Morgan Stanley Analyst forecast on GMED
Morgan Stanley
Morgan Stanley
$70$100
Buy
6.99%
Upside
Reiterated
12/02/25
Globus Medical price target raised to $100 from $70 at Morgan StanleyGlobus Medical price target raised to $100 from $70 at Morgan Stanley
Citizens JMP Analyst forecast on GMED
Citizens JMP
Citizens JMP
Hold
Reiterated
08/20/25
Citizens JMP Remains a Hold on Globus Medical (GMED)
Roth MKM Analyst forecast on GMED
Roth MKM
Roth MKM
$105
Buy
12.34%
Upside
Reiterated
08/08/25
Roth MKM Reaffirms Their Buy Rating on Globus Medical (GMED)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on GMED
Bank of America Securities
Bank of America Securities
$106
Buy
13.41%
Upside
Reiterated
01/16/26
Globus Medical (GMED) Gets a Buy from Bank of America Securities
Canaccord Genuity Analyst forecast on GMED
Canaccord Genuity
Canaccord Genuity
$105$112
Buy
19.82%
Upside
Reiterated
01/09/26
Canaccord Genuity Remains a Buy on Globus Medical (GMED)
Truist Financial Analyst forecast on GMED
Truist Financial
Truist Financial
Buy
Reiterated
01/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Neogen (NASDAQ: NEOG), Radnet (NASDAQ: RDNT) and Globus Medical (NYSE: GMED)
Jefferies
$105$115
Buy
23.03%
Upside
Reiterated
01/08/26
Jefferies Sticks to Its Buy Rating for Globus Medical (GMED)
Barclays Analyst forecast on GMED
Barclays
Barclays
$114$118
Buy
26.24%
Upside
Reiterated
01/08/26
Barclays Keeps Their Buy Rating on Globus Medical (GMED)
Stifel Nicolaus Analyst forecast on GMED
Stifel Nicolaus
Stifel Nicolaus
$76$90
Hold
-3.71%
Downside
Reiterated
01/08/26
Analysts Offer Insights on Healthcare Companies: Globus Medical (NYSE: GMED) and Verrica Pharmaceuticals (NASDAQ: VRCA)
Wells Fargo Analyst forecast on GMED
Wells Fargo
Wells Fargo
$98
Buy
4.85%
Upside
Reiterated
01/08/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Globus Medical (GMED)
Needham
Hold
Reiterated
01/08/26
Globus Medical: Strong Fundamentals and Outperformance Largely Priced In, Justifying a Hold Rating
Piper Sandler Analyst forecast on GMED
Piper Sandler
Piper Sandler
$90$115
Buy
23.03%
Upside
Reiterated
01/08/26
Piper Sandler Reaffirms Their Buy Rating on Globus Medical (GMED)
RBC Capital
$100$115
Buy
23.03%
Upside
Reiterated
01/07/26
RBC Capital Reaffirms Their Buy Rating on Globus Medical (GMED)
BTIG
Hold
Reiterated
01/07/26
Globus Medical: Strong Execution and Upside Revisions Balanced by Full Valuation Support Hold Rating
Freedom Capital Markets Analyst forecast on GMED
Freedom Capital Markets
Freedom Capital Markets
$87
Hold
-6.92%
Downside
Initiated
12/16/25
Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN) and Globus Medical (NYSE: GMED)
Morgan Stanley Analyst forecast on GMED
Morgan Stanley
Morgan Stanley
$70$100
Buy
6.99%
Upside
Reiterated
12/02/25
Globus Medical price target raised to $100 from $70 at Morgan StanleyGlobus Medical price target raised to $100 from $70 at Morgan Stanley
Citizens JMP Analyst forecast on GMED
Citizens JMP
Citizens JMP
Hold
Reiterated
08/20/25
Citizens JMP Remains a Hold on Globus Medical (GMED)
Roth MKM Analyst forecast on GMED
Roth MKM
Roth MKM
$105
Buy
12.34%
Upside
Reiterated
08/08/25
Roth MKM Reaffirms Their Buy Rating on Globus Medical (GMED)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Globus Medical

3 Months
xxx
Success Rate
15/23 ratings generated profit
65%
Average Return
+4.55%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.22% of your transactions generating a profit, with an average return of +4.55% per trade.
1 Year
Matt MiksicBarclays
Success Rate
23/31 ratings generated profit
74%
Average Return
+19.12%
reiterated a buy rating 11 days ago
Copying Matt Miksic's trades and holding each position for 1 Year would result in 74.19% of your transactions generating a profit, with an average return of +19.12% per trade.
2 Years
xxx
Success Rate
29/31 ratings generated profit
94%
Average Return
+35.93%
reiterated a xxx
rating 11 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 93.55% of your transactions generating a profit, with an average return of +35.93% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GMED Analyst Recommendation Trends

Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
9
5
1
1
0
Buy
23
29
46
36
40
Hold
13
7
5
7
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
41
52
44
47
In the current month, GMED has received 40 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. GMED average Analyst price target in the past 3 months is 105.60.
Each month's total comprises the sum of three months' worth of ratings.

GMED Financial Forecast

GMED Earnings Forecast

Next quarter’s earnings estimate for GMED is $1.11 with a range of $0.92 to $1.26. The previous quarter’s EPS was $1.18. GMED beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.
Next quarter’s earnings estimate for GMED is $1.11 with a range of $0.92 to $1.26. The previous quarter’s EPS was $1.18. GMED beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.

GMED Sales Forecast

Next quarter’s sales forecast for GMED is $792.72M with a range of $767.50M to $823.20M. The previous quarter’s sales results were $769.05M. GMED beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.
Next quarter’s sales forecast for GMED is $792.72M with a range of $767.50M to $823.20M. The previous quarter’s sales results were $769.05M. GMED beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year GMED has Performed in-line its overall industry.

GMED Stock Forecast FAQ

What is GMED’s average 12-month price target, according to analysts?
Based on analyst ratings, Globus Medical’s 12-month average price target is 105.60.
    What is GMED’s upside potential, based on the analysts’ average price target?
    Globus Medical has 12.98% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GMED a Buy, Sell or Hold?
          Globus Medical has a consensus rating of Moderate Buy which is based on 9 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Globus Medical’s price target?
            The average price target for Globus Medical is 105.60. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $118.00 ,the lowest forecast is $87.00. The average price target represents 12.98% Increase from the current price of $93.47.
              What do analysts say about Globus Medical?
              Globus Medical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of GMED?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.